tradingkey.logo

Prenetics Global Ltd

PRE
18.380USD
+0.900+5.15%
收盤 12/22, 16:00美東報價延遲15分鐘
236.99M總市值
虧損本益比TTM

Prenetics Global Ltd

18.380
+0.900+5.15%

關於 Prenetics Global Ltd 公司

Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.

Prenetics Global Ltd簡介

公司代碼PRE
公司名稱Prenetics Global Ltd
上市日期Jul 06, 2021
CEOKwok (Samantha)
員工數量285
證券類型Ordinary Share
年結日Jul 06
公司地址Unit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay
城市
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Hong Kong
郵編- -
電話85222109588
網址https://ir.prenetics.com/
公司代碼PRE
上市日期Jul 06, 2021
CEOKwok (Samantha)

Prenetics Global Ltd公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Kathryn Henry
Ms. Kathryn Henry
Independent Director
Independent Director
--
--
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Mr. David Vanderveen
Mr. David Vanderveen
Independent Director
Independent Director
--
--
Ms. Jordan Lemerande
Ms. Jordan Lemerande
Vice President - Product Development
Vice President - Product Development
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Ms. Wing Kwan (Winnie) Chiu
Ms. Wing Kwan (Winnie) Chiu
Independent Director
Independent Director
--
--
Mr. Joel Neoh
Mr. Joel Neoh
Chief Consumer Officer, Chief Executive Officer of CircleDNA
Chief Consumer Officer, Chief Executive Officer of CircleDNA
--
--
Mr. Alan Thomas
Mr. Alan Thomas
Vice President, Supply Chain & Operations
Vice President, Supply Chain & Operations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Kathryn Henry
Ms. Kathryn Henry
Independent Director
Independent Director
--
--
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Mr. David Vanderveen
Mr. David Vanderveen
Independent Director
Independent Director
--
--
Ms. Jordan Lemerande
Ms. Jordan Lemerande
Vice President - Product Development
Vice President - Product Development
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
Hong Kong
14.27M
46.59%
Taiwan
7.09M
23.16%
The United States
5.51M
18.00%
United Kingdom
2.78M
9.08%
Rest of the world
972.00K
3.17%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 12月17日 週三
更新時間: 12月17日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Dennis (Lo Yuk Ming)
7.69%
Genetel Bioventures Ltd
4.90%
Lawrence (Tzang Chi Hung)
4.29%
Eastspring Investments (Singapore) Limited
3.42%
Aspex Management (HK) Limited
2.76%
其他
76.94%
持股股東
持股股東
佔比
Dennis (Lo Yuk Ming)
7.69%
Genetel Bioventures Ltd
4.90%
Lawrence (Tzang Chi Hung)
4.29%
Eastspring Investments (Singapore) Limited
3.42%
Aspex Management (HK) Limited
2.76%
其他
76.94%
股東類型
持股股東
佔比
Individual Investor
13.28%
Corporation
4.90%
Investment Advisor
3.77%
Hedge Fund
2.97%
Research Firm
2.63%
Investment Advisor/Hedge Fund
0.68%
Bank and Trust
0.35%
其他
71.43%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
23
1.16M
9.26%
-1.28M
2025Q2
30
3.73M
32.59%
-1.27M
2025Q1
31
3.72M
35.24%
-295.48K
2024Q4
35
3.71M
34.90%
-336.29K
2024Q3
37
3.69M
34.65%
-448.54K
2024Q2
38
3.76M
35.34%
-535.47K
2024Q1
88
5.56M
55.93%
+1.27M
2023Q4
94
4.17M
42.91%
+30.90K
2023Q3
99
4.01M
43.06%
+108.37K
2023Q2
98
3.11M
36.85%
-918.88K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Dennis (Lo Yuk Ming)
962.96K
8.41%
--
--
Apr 24, 2025
Genetel Bioventures Ltd
613.79K
5.36%
--
--
Sep 30, 2024
Lawrence (Tzang Chi Hung)
537.10K
4.69%
--
--
Apr 24, 2025
Eastspring Investments (Singapore) Limited
427.96K
3.74%
--
--
Jun 30, 2025
Aspex Management (HK) Limited
346.15K
3.02%
--
--
Jun 30, 2025
Nomura Securities Co., Ltd.
321.82K
2.81%
-11.70K
-3.51%
Jun 30, 2025
Chun (Lo Hoi)
162.62K
1.42%
--
--
Apr 24, 2025
UBS Switzerland AG
394.00
0%
-706.00
-64.18%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.03%
iShares Micro-Cap ETF
佔比0.03%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
公告日期
類型
比率
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1

常見問題

Prenetics Global Ltd的前五大股東是誰?

Prenetics Global Ltd的前五大股東如下:
Dennis (Lo Yuk Ming)
持有股份:962.96K
佔總股份比例:8.41%。
Genetel Bioventures Ltd
持有股份:613.79K
佔總股份比例:5.36%。
Lawrence (Tzang Chi Hung)
持有股份:537.10K
佔總股份比例:4.69%。
Eastspring Investments (Singapore) Limited
持有股份:427.96K
佔總股份比例:3.74%。
Aspex Management (HK) Limited
持有股份:346.15K
佔總股份比例:3.02%。

Prenetics Global Ltd的前三大股東類型是什麼?

Prenetics Global Ltd 的前三大股東類型分別是:
Dennis (Lo Yuk Ming)
Genetel Bioventures Ltd
Lawrence (Tzang Chi Hung)

有多少機構持有Prenetics Global Ltd(PRE)的股份?

截至2025Q3,共有23家機構持有Prenetics Global Ltd的股份,合計持有的股份價值約為1.16M,占公司總股份的9.26% 。與2025Q2相比,機構持股有所增加,增幅為-23.33%。

哪個業務部門對Prenetics Global Ltd的收入貢獻最大?

在FY2024,--業務部門對Prenetics Global Ltd的收入貢獻最大,創收--,占總收入的--% 。
KeyAI